[Form 4] Elanco Animal Health Inc Insider Trading Activity

Rhea-AI Filing Summary

Elanco Animal Health general counsel and corporate secretary Shiv O'Neill reported equity compensation changes. On March 1, 2026, O'Neill received 29,993 stock options and 33,087 shares of common stock as grant or award acquisitions, all held directly.

The filing also shows a grant of an additional 14,679 common shares and a tax-withholding disposition of 13,111 common shares at $26.40 per share to cover tax obligations. The options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.

Insider Trade Summary

Net Buyer: 34,655 shares

Net Buy 4 txns

Insider O'Neill Shiv

Role GC AND CORP SEC

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	29,993	$0.00	$0.00
Grant/Award	Common Stock	33,087	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	13,111	$26.40	$346K
Grant/Award	Common Stock	14,679	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 29,993 shares (Direct); Common Stock — 88,572 shares (Direct)

Footnotes (2)

1. F1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
2. F2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 07:15 PM Learn about SEC filing dates

FAQ

What insider transactions did Elanco (ELAN) report for Shiv O'Neill?

Elanco reported that general counsel Shiv O'Neill received stock options and common stock grants, plus a tax-withholding share disposition. These transactions reflect equity compensation awards and related tax settlement rather than open-market buying or selling activity.

How many Elanco (ELAN) stock options did Shiv O'Neill acquire?

Shiv O'Neill acquired 29,993 Elanco employee stock options in a grant. These options were awarded at a stated price of $0.00 per option and vest over three years, beginning in 2027 and ending in 2029.

How many Elanco (ELAN) common shares were granted to Shiv O'Neill?

Shiv O'Neill received two common stock grants totaling 47,766 shares (33,087 plus 14,679). These awards were reported as grant or award acquisitions with a price per share of $0.00, reflecting equity compensation rather than purchases.

What is the vesting schedule for Shiv O'Neill’s Elanco (ELAN) equity awards?

Both the restricted stock units and stock options vest in three equal parts. One-third vests on March 1, 2027, another third on March 1, 2028, and the remaining portion vests on March 1, 2029, creating a multi-year incentive structure.

Why did Shiv O'Neill dispose of Elanco (ELAN) shares in this Form 4?

The Form 4 shows disposition of 13,111 Elanco common shares under transaction code F. This indicates shares were withheld at $26.40 per share to pay exercise price or tax liabilities tied to the equity awards, not an open-market sale.

How many Elanco (ELAN) shares does Shiv O'Neill hold after these transactions?

After the reported transactions, Shiv O'Neill directly holds 88,572 Elanco common shares in one of the award lines. The Form 4 presents this as the total shares following that acquisition entry, reflecting updated direct ownership from the grants and withholdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neill Shiv

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GC AND CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		33,087	A	$0	87,004	D
Common Stock	03/01/2026		F		13,111	D	$26.4	73,893	D
Common Stock	03/01/2026		A		14,679(1)	A	$0	88,572	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.4	03/01/2026		A		29,993		(2)	03/01/2036	Common Stock	29,993	$0	29,993	D

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

2. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Shiv O'Neill	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.